Felipe M. Heiderich

• Ouro Medicines in its acquisition by Gilead Sciences for up to $2.375 billion
• Orna Therapeutics in its acquisition by Eli Lilly & Company for up to $2.4 billion
• Limmatech Biologics in its acquisition by Eli Lilly & Company for up to $780 million
• Sail Biomedicines in its strategic collaboration and option to be acquired by Johnson & Johnson for $780 million upfront and $2.58 billion at option exercise
• Moderna in its acquisition of OriCiro Geonomics K.K., a Japanese synthetic DNA company*
• Moderna’s acquisition of FDA Priority Review Vouchers from various sellers* 
• Johnson & Johnson in over $1 billion in acquisitions and divestitures
• Volkswagen Truck & Bus in its $250 million investment and strategic technology partnership with Navistar International*
• Amazon in its $580 million acquisition of Souq.com*
• Amazon in its acquisition of Sqrrl*
• Solvay in its $6.4 billion acquisition of Cytec Industries*
• Various sponsor-backed private technology companies in acquisitions and exits of middle-market software businesses* 

• Quotient Therapeutics in its multi-year research collaboration with Merck for up to $2.2 billion
• Moderna in its strategic collaboration with Recordati for $50 million upfront and up to an additional $110 million in near-term development and regulatory milestones
• ProFound Therapeutics in its four-year collaboration with Novartis for an upfront payment of $25 million and up to $750 million in milestone payments
• Moderna in its research and development collaboration with Immatics N.V. for up to $1.7 billion*
• Moderna in its research and development collaboration with Generation Bio Co. for up to $1.8 billion*
• Moderna in its research and development collaboration with LifeEdit Therapeutics, Inc. and ElevateBio, LLC*
• Moderna in its research and development collaboration with CytomX Therapeutics, Inc. for up to $1.2 billion*
• Moderna’s long-term, multi-billion-dollar manufacturing, supply, and R&D partnerships with the governments of the UK, Australia, and Canada* 

• Forbion and Novartis Ventures as lead investors in Protego Biopharma's $130 million Series B financing
• BeOne Medicines in its sale of royalty rights on the worldwide sales, excluding China, of Amgen’s IMDELLTRA® (tarlatamab-dlle) for up to $950 million to Royalty Pharma
• Moderna in its $750 million research and development funding collaboration with Blackstone Life Sciences*
• Moderna’s PIPE investment in Generation Bio Co. in connection with the collaboration between the companies*
• Moderna’s convertible note investment in Carisma Therapeutics, Inc. and subsequent reverse merger, in connection with the collaboration between the companies*
• Moderna’s preferred equity investment in Metagenomi, Inc’s Series B financing*
• Various venture-backed technology companies in connection with venture financing rounds led by venture capital funds and strategic investors*  
• Various corporate venture funds in connection with investments in venture-backed businesses* 

*Denotes experience prior to joining Goodwin